Fatty liver drug shows promise in small trial
NCT ID NCT05364684
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested a drug called ibutamoren in 12 adults with nonalcoholic fatty liver disease (NAFLD). The goal was to see if it could lower fat in the liver. Participants took the drug for 6 months, and researchers measured liver fat using special MRI scans. The study was small and early-stage, so results are not yet conclusive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could immune cells in fat hold the key to Obesity-Related diseases?
- Could estrogen patch reverse liver damage in postmenopausal women?
- A new MRI technique could see inside the Liver's metabolism without a biopsy
- Could a common b vitamin tame fatty liver?
- Can a sugar test reveal how fatty liver begins in obese adolescents?
- Could a daily dose of citrus fiber tame fatty liver inflammation?